

Supplement Table 2. Factors Associated with Virological First-line ART Failure

Variable	Classification	Suppressed N (%)	Failed N (%)	AOR (95%CI)	P-value
Sex	Female	146 (90.68)	15 (9.32)	1	
	Male	80 (85.11)	14 (14.89)	1.852 (0.566, 6.061)	0.06
Age at Enrollment	≥ 35	115 (91.27)	11 (8.73)	1	
	25 – 34	81 (87.10)	12 (12.90)	1.530 (0.377, 6.214)	0.056
	15 - 24	24 (80)	6 (20)	2.126 (0.302, 14.970)	0.082
Clinical Characteristics at Enrollment					
BMI at Enrollment (kg/m²)	18.5 - 24.99	120 (93.75)	8 (6.25)	1	
	< 18.5	53 (81.54)	12 (18.46)	3.717 (1.051, 13.139)	0.02*
	> 24.99	33 (89.19)	4 (10.81)	1.322 (0. 108, 16.210)	0.074
Serostatus Disclosure	Yes	153 (92.17)	13 (7.83)	1	
	No	67 (81.71)	15 (18.29)	4.453 (1.340, 14.793)	0.001*
WHO Stages at Enrollment	I & II	122 (89.71)	14 (10.29)	1	
	III & IV	56 (83.58)	11 (16.42)	3.036 (0.898, 10.267)	0.057
Duration of ART Initiation (in Days)	early (≤ 30 days)	137 (93.20)	10 (6.80)	1	
	late (> 30 days)	72 (80.00)	18 (20.00)	4.249 (1.164, 15.512)	0.02*
Clinical Characteristics During Follow-up					
History of Missed ART Doses	No	148 (93.08)	11 (6.92)	1	
	Yes	63 (79.75)	16 (20.25)	3.156 (1.007, 9.891)	0.03*
DTG Based Regimen	No	81 (81.82)	18 (18.18)	1	
	Yes	147 (93.04)	11 (6.94)	0.275 (0. 085, 0.895)	0.001*
Duration on ART (in Months)	≤ 24	100 (94.34)	6 (5.66)	1	
	> 24	126 (84.56)	23 (15.44)	2.821 (0.775, 10.273)	0.53*

*- statistically significant at p-value < 0.05.